Multiple Myeloma Research and Treatments

Personalised prediction of anomalous bone regeneration in multiple myeloma patients

This study develops computational models to predict bone regeneration in multiple myeloma patients using patient data and genomics, showing rapid strengthening not fully explained by known mechanisms.

Genomic characterization of patient derived xenograft models of multiple myeloma reveals selection of multiple pre-existing high risk clones

This study uses SCID-rab PDX models to analyze genomic and transcriptomic features of multiple myeloma, revealing selection of pre-existing high-risk clones.

A platform for deep topographic multiomic mapping of the bone marrow environment in multiple myeloma

The paper develops a spatial tri-omics workflow to map genetically distinct myeloma subclones in bone marrow, showing they occupy spatially and biologically distinct niches.

Deconvolution of the mechanisms of T cell drug response in multiple myeloma induction therapy

This study investigates the molecular effects of RVd therapy on T cells using TEA-seq, revealing how individual and sequential drug administration impacts T cell function and states.

C1Q-associated adaptive myeloid remodelling accompanies early response to BCMA CAR-T therapy in multiple myeloma

In a ten-patient multiple myeloma reanalysis, myeloid pseudobulk from day-30 BCMA CAR-T responders showed C1Q enrichment with interferon-γ signalling, not cholesterol efflux; patient-level composite scores stayed exploratory.

Integration of clinical and T-cell immune profiling to predict early response to CD3xBCMA bispecific antibody immunotherapy in Multiple Myeloma

This study integrates clinical and T-cell immune profiling to identify early biomarkers of response to CD3xBCMA bispecific antibody therapy in multiple myeloma.

Translating multi-omics complexity into sparse prognostic biomarkers for multiple myeloma

This paper identifies prognostic biomarkers for multiple myeloma by integrating multi-omics data and shows that proteomic features outperform genomic or transcriptomic data in classification.

Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myeloma

This study shows that c-Myc protein stability determines the response of Ras-mutant multiple myeloma cells to RAS and MEK inhibitors, suggesting direct RAS targeting is more effective.

A Circulating TLR2pos CD14neg CD16neg '' Unclassified Subset '' is Decreased in Multiple Myeloma Patients and May Comprise CD163pos Dendritic Cells.

The paper identifies a previously overlooked TLR2pos CD14neg CD16neg subset in blood that may represent CD163pos dendritic cells, which are reduced in multiple myeloma patients.

Menin regulates oncogenic cell identity transcriptional networks in multiple myeloma

This study identifies Menin as a key regulator of oncogenic gene expression in multiple myeloma and shows that Menin inhibitors are effective in myeloma cell lines and models.

Profound CD4+ T-Cell Reprogramming by Melphalan-Driven Oxidative Stress in High-Risk Multiple Myeloma

This study shows that melphalan treatment causes oxidative stress in T cells, reducing CD4+ naive T cells in high-risk multiple myeloma patients.

Germline regulation of tumor evolutionary dynamics shapes multiple myeloma progression

This study links germline variation to tumor evolutionary dynamics in multiple myeloma, identifying TBKBP1 as a mediator of subclonal expansion and clinical outcomes.

Sequential acquisition of 1p31.1-p12 LOH and 1q Gain is a common double-hit event in relapsed/refractory myeloma

The paper identifies a therapy-driven genomic double-hit (1pCEN LOH and 1q gain) in relapsed/refractory myeloma, associated with poor prognosis and clonal expansion.

Schlafen 11 (SLFN11) overexpression in multiple myeloma and nucleolar translocation in response to bortezomib

This study shows SLFN11 is highly expressed in multiple myeloma and normal plasma cells, and its nucleolar translocation in response to bortezomib correlates with drug resistance and therapeutic benefit.

Mast Cells Enhance Myeloma Engraftment and Promote Bone Destruction in the NSG-hIL6 Patient Derived Xenograft Model

This study shows mast cells enhance myeloma engraftment and promote bone destruction in the NSG-hIL6 xenograft model by secreting factors that improve myeloma cell survival.

Myeloma and therapy reshape the bone marrow niche to durably constrain immune reconstitution and vaccine responsiveness

This study shows how multiple myeloma and its treatment alter the bone marrow niche, impairing immune reconstitution and vaccine responses, with mRNA vaccines showing better efficacy than influenza vaccines.

Dynamic multimodal survival prediction in multiple myeloma integrating gene expression, longitudinal laboratories, and treatment history

This paper develops a dynamic multimodal model for survival prediction in multiple myeloma using gene expression, lab data, and treatment history, achieving higher accuracy than existing methods.

Spatial multi-omics of multiple myeloma uncovers niche-dependent pro-myeloma and immunosuppressive signaling in the bone marrow and extramedullary lesions

This study uses spatial and single-cell transcriptomics to identify niche-specific signaling programs in multiple myeloma that drive progression and immunosuppression.

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma

The paper identifies genomic and transcriptional changes in multiple myeloma cells that drive resistance to anti-BCMA therapies, termed 'plasma cell identity escape'.

CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma

This paper shows CDK4/6 inhibition enhances immunomodulatory drug therapy in multiple myeloma by reversing MEIS2 suppression of CRL4CRBN and reducing BCMA signaling.

Whole genome CRISPR knockout screen reveals ID3 as a key regulator of myeloma cell survival via TCF3 and c-MYC

Highly multiplexed imaging recovers immune and metabolic niches in multiple myeloma associated with disease progression and bone involvement

This study uses spatial analysis to identify immune and metabolic niches in multiple myeloma, finding that CD4+ T cell proximity predicts disease progression.

Longitudinal multi-omic profiling uncovers immune escape and predictors of response in multiple myeloma

This study uses longitudinal multi-omic profiling to identify immune escape mechanisms and predictors of response in multiple myeloma.

Novel SLAMF1-derived peptide induces apoptosis in multiple myeloma cells by targeting IRF4 transcription factor for degradation

This study identifies a SLAMF1-derived peptide, P7N4, that induces apoptosis in multiple myeloma cells by degrading IRF4, enhancing chemotherapy efficacy and showing minimal toxicity to healthy cells.

Exploiting macropinocytosis for therapeutic intervention in RAS mutant Multiple Myeloma

This paper develops a monobody-drug conjugate targeting mutant RAS in multiple myeloma, showing improved anti-tumor effects and safety in vitro and in vivo.

Novel Pan-ALDH Inhibitor KS100 Effectively Targets ALDH+/CD138- Stem-like Cells to Overcome Relapse in Multiple Myeloma

This study identifies KS100, a pan-ALDH inhibitor, as effective in reducing ALDH expression and viability of multiple myeloma cells, particularly ALDH+/CD138- stem-like cells, potentially overcoming relapse.

High cholesterol increases myeloma tumour burden and promotes resistance to bortezomib

This study shows high cholesterol increases myeloma tumour burden and promotes resistance to bortezomib by elevating resistin levels in bone marrow.

Machine Learning Models for Predicting Multiple Myeloma Staging and MGUS Progression Using Gene Expression Data

This study develops ML models to predict multiple myeloma staging and MGUS progression using gene expression data, achieving AUC values above 0.8 with ElasticNet and other algorithms.

Stage-specific gene ratios highlight genes and mechanisms related to presymptomatic and symptomatic Multiple Myeloma

The paper identifies stage-specific genes and pathways in Multiple Myeloma using monotonic expressed genes (MEGs) and gene pair ratios, showing their potential as biomarkers for disease progression.

Germline and somatic genetic effects on gene expression and outcome in patients with Multiple Myeloma

This study identifies germline and somatic genetic effects on gene expression and patient outcomes in Multiple Myeloma using matched genotype and expression data from 607 patients.